Home
About
Our Pipeline
SPC-14
Targeting Alzheimer’s
SPC-15
Targeted prophylactic treatment—Stress-induced affective disorders
SP-26
Time-Released Psilocybin, Ketamine
SPU-16
CNS Homing Peptide targeting Multiple Sclerosis
SPU-21
Arthritogenic Joint Homing Peptides Utilizing Psilocybin
Drugs in the pipeline
View our current pipeline
SPC-14
SPC-15
SPU-16
SPU-21
SP-26
Studies
Clinical Studies
Clinical Study I
Repeated Low Doses of Ketamine & Psilocybin on Parkinson's Disease
Investigator-Sponsored Study Agreement—Maastricht University of the Netherlands
Clinical Studies
Clinical Study II
Effect of Psilocybin on Inflammation in the Blood
Sponsored Research Agreement—University of California, San Francisco (UCSF)
Drugs in the pipeline
View our current pipeline
Study
Investors
Contact Us
Select Page
Logo 8
May 27, 2022
Search for:
